Holding company.
Location: United States, New York
Employees: 1-10
Investment Type: Venture Capital
Portfolio 42
| Date | Name | Website | Total Raised | Location |
| 21.01.2026 | Think Bios... | thinkbioscience.com | $98M | United Sta... |
| 12.10.2025 | Juniper | junipergenomics.com | - | - |
| 12.10.2025 | Enoda Cell... | enoda.bio | - | - |
| 12.10.2025 | Keebler He... | keebler.health | $22M | United Sta... |
| 12.10.2025 | Persist AI | persist-ai.com | $16M | United Sta... |
| 12.10.2025 | Rula | rula.com | - | - |
| 02.12.2024 | Examol | examol.io | - | - |
| 02.12.2024 | Junction H... | junction-health.com | - | - |
| 02.12.2024 | Tidal Visi... | tidalvision.com | $140M | United Sta... |
| 10.03.2024 | Smiles.ai | smiles.ai | $23M | South Afri... |
Show more
Mentions in press and media 20
| Date | Title | Description |
| 15.04.2026 | Keebler Health Raises $16M in Series A Funding | Keebler Health, a Durham, NC-based LLM-native health technology company, raised $16M in Series A funding. The round was led by Flare Capital Partners, with participation from Sands Capital and existing investors including Aviano Ventures, E... |
| 22.01.2026 | Think Bioscience Secures $55M Series A for 'Undruggable' Target Therapies | Think Bioscience, a Boulder, CO-based drug discovery innovator, closed an oversubscribed $55 million Series A funding round. This substantial investment accelerates R&D and operational expansion. The firm pioneers small molecule therape... |
| 20.01.2026 | Think Bioscience Raises $55M in Series A Funding | Think Bioscience, a Boulder, CO-based privately held small molecule drug discovery company, raised $55M in Series A funding. The round was led byRegeneron Ventures, Innovation Endeavors, and Janus Henderson Investors with participation from... |
| 16.12.2025 | Why MBX Capital is Betting $100M on the Link Between Industrial Toxins and Chronic Disease | What You Should Know: – MBX Capital has secured over $100M in capital commitments to invest in early-stage biotech and health tech companies, specifically focusing on “deep health” solutions that address diseases linked to environmental tox... |
| 30.05.2025 | Vivodyne Secures $40M Series A to Scale AI-Powered Human Tissue Testing | What You Should Know: – Vivodyne, a company pioneering an exclusively human-focused preclinical process, today announced it has raised $40M in new Series A funding led by Khosla Ventures, with participation from new investors Lingotto Inves... |
| 20.05.2025 | Persist AI: Revolutionizing Drug Development with Cloud Lab and $12 Million Funding | In the fast-paced world of pharmaceuticals, time is money. The race to bring new drugs to market is relentless. Enter Persist AI, a trailblazer in AI-driven robotics for pharmaceutical formulation development. Recently, the company announce... |
| 20.05.2025 | Persist AI: $12 Million Series A Raised And Cloud Lab Launched | Persist AI, a pioneer in AI-based robotics for pharmaceutical formulation development and Chemistry, Manufacturing, and Controls (CMC), announced the launch of its Cloud Lab platform following the closing of an oversubscribed $12 million Se... |
| 20.05.2025 | Persist AI Launches Cloud Lab to Accelerate Pharmaceutical Formulation Development, Raises $12Million Series A Funding | AI-driven robotics platform reduces drug formulation development time from years to months Persist AI, a pioneer in AI-driven robotics for pharmaceutical formulation development and Chemistry, Manufacturing, and Controls (CMC), today announ... |
| 05.05.2025 | CND Life Sciences: Pioneering Neurodiagnostics with $13.5 Million Boost | In the ever-evolving landscape of healthcare, innovation is the lifeblood that fuels progress. CND Life Sciences, a neurodiagnostics startup based in Scottsdale, Arizona, has just secured a significant financial boost of $13.5 million in it... |
| 04.05.2025 | CND Life Sciences: $13.5 Million Series A Closed For Neurodiagnostics Innovations | CND Life Sciences announced that it has raised $13.5 million in its Series A equity financing round, with $8.6 million in its most recent Series A3 offering. CND’s latest Series A3 round included funding from existing investor groups like C... |
Show more